



## **PEAR THERAPEUTICS TO PARTICIPATE IN EVERCORE ISI FOURTH ANNUAL HEALTHCONX CONFERENCE**

November 23, 2021

**BOSTON, November 23, 2021** – [Pear Therapeutics, Inc.](#), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced management will participate in the Evercore ISI Fourth Annual HealthCONx Conference on Wednesday, December 1, 2021. Corey McCann, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at 8:50 a.m. ET.

A live audio webcast can be accessed by clicking [here](#) and will be made available on Pear's website at [www.peartherapeutics.com](http://www.peartherapeutics.com). A replay will be available for approximately 30 days following the live presentation.

### **About Pear Therapeutics**

Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear's lead product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from FDA to treat disease. Pear's second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear's third product, Somryst™, for the treatment of chronic insomnia, was the first PDT submitted through FDA's traditional 510(k) pathway while simultaneously reviewed through FDA's Software Precertification Pilot Program. For more information, visit Pear at [www.peartherapeutics.com](http://www.peartherapeutics.com).

### **Media and Investors:**

Meara Murphy

Senior Director, Corporate Communications

[meara.murphy@peartherapeutics.com](mailto:meara.murphy@peartherapeutics.com)